BridgeBio Oncology Therapeutics (BBOT) Share-based Compensation (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Share-based Compensation of $61.5 million for Q1 2026, up 4215.79% sequentially from $1.4 million in Q3 2025, and up 9708.61% YoY from $627000.0 in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Share-based Compensation (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Share-based Compensation for 3 years, with the latest figure at $61.5 million in Q1 2026.
- Quarterly Share-based Compensation rose 9708.61% year-over-year to $61.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.5 million (up 1449.9% YoY) and the FY2025 annual result came in at $41.2 million, up 1695.99% from the prior year.
- Share-based Compensation rose to $61.5 million in Q1 2026 per BBOT's latest filing, from $1.4 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $61.5 million in Q1 2026 and troughed at $279000.0 in Q2 2024.
- A 3-year average of $8.6 million and a median of $821500.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation retreated 5.0% in 2025, then jumped 9708.61% in 2026.
- Over 3 years, Share-based Compensation stood at $2.3 million in 2024, then slumped by 37.88% to $1.4 million in 2025, then jumped by 4215.79% to $61.5 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $61.5 million, $1.4 million, and $875000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 7.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.23 Mn |
| Jun 30, 2026 | 7.23 Mn |
| Mar 31, 2026 | 61.50 Mn |
| Mar 31, 2026 | 61.50 Mn |
| Sep 30, 2025 | 1.43 Mn |
| Sep 30, 2025 | 1.43 Mn |
| Jun 30, 2025 | 875,000.00 |
| Jun 30, 2025 | 875,000.00 |
| Mar 31, 2025 | 627,000.00 |
| Mar 31, 2025 | 627,000.00 |
| Dec 31, 2024 | 2.29 Mn |
| Dec 31, 2024 | 2.29 Mn |
| Sep 30, 2024 | 768,000.00 |
| Sep 30, 2024 | 768,000.00 |
| Jun 30, 2024 | 279,000.00 |
| Jun 30, 2024 | 279,000.00 |
| Mar 31, 2024 | 660,000.00 |
| Mar 31, 2024 | 660,000.00 |